HEPA
HEPION PHARMS INC
stockOTC
hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.08 | 2026-09-28 | +1.25% | -42.791 |
| 1M | 0.09 | 2026-09-04 | -7.96% | 8.232 |
| 3M | 0.08 | 2026-07-06 | +2.53% | -2.457 |
| 6M | 0.06 | 2026-04-06 | +47.27% | -0.248 |
| 1Y | 0.07 | 2025-10-03 | +17.73% | 1.725 |
| 2Y | 32.50 | 2024-10-04 | -99.75% | — |
| 5Y | 1,520.00 | 2021-10-04 | -100.00% | 0.177 |
HEPION PHARMS INC (OTC:HEPA) stock price today is $0.08, and today's volume is 26,491. HEPA is down 19.000% today. The 30 day average volume is 46,622. HEPA market cap is $885,109 with 10.93M shares outstanding.